checkAd

    DGAP-Adhoc  1162  0 Kommentare WILEX AG: WILEX signs antibody license agreement with Telix Pharmaceuticals Limited





    DGAP-Ad-hoc: WILEX AG / Key word(s): Alliance


    WILEX AG: WILEX signs antibody license agreement with Telix Pharmaceuticals Limited


    16-Jan-2017 / 09:05 CET/CEST


    Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.


    The issuer is solely responsible for the content of this announcement.



    Ad-hoc announcement

    Inside information according to Article 17 MAR

    WILEX signs antibody license agreement with Telix Pharmaceuticals Limited

    Munich, Germany, 16 January 2017 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE)
    and Australian biopharmaceutical company Telix Pharmaceuticals Limited
    ("Telix"), today announced that they have concluded a worldwide license
    agreement for the development and commercialization of the imaging agent
    REDECTANE(R), a radiolabeled form of the monoclonal antibody Girentuximab.
    WILEX successfully completed a first Phase III trial with REDECTANE(R) in
    ccRCC.

    WILEX has granted Telix the worldwide licensing rights to further develop
    and commercialize the REDECTANE(R) molecular imaging program. Under the
    agreement, Telix will, as a first step, invest in an improved manufacturing
    process for the antibody. Under the terms of the agreement, WILEX is
    eligible to receive up-front and milestone payments totaling USD 3.7
    million. In addition, WILEX is eligible to receive significant royalties on
    global net sales of REDECTANE(R), commensurate with a Phase III asset.
    Telix will be responsible for all development costs, as well as
    manufacturing and commercialization costs.

    Telix will also develop a therapeutic radioimmunoconjugate program based on
    Girentuximab. Early clinical data suggests that 177Lu-labeled Girentuximab
    has disease stabilizing effects in patients with advanced staged metastatic
    renal cancer. Telix is evaluating the use of CAIX targeting therapeutic
    agents with both beta- and alpha-emitting radionuclides for a variety of
    malignancies. Under the terms of the agreement, if a therapeutic product
    developed by Telix is ultimately granted marketing approval, WILEX will
    receive single-digit royalties.

    Seite 1 von 3


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-Adhoc WILEX AG: WILEX signs antibody license agreement with Telix Pharmaceuticals Limited DGAP-Ad-hoc: WILEX AG / Key word(s): Alliance WILEX AG: WILEX signs antibody license agreement with Telix Pharmaceuticals Limited 16-Jan-2017 / 09:05 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a …

    Schreibe Deinen Kommentar

    Disclaimer